2024 WCLC | 标题公布！共70+项口头报告，中国之声抢先一览！|医学|讲者|wclc|上海市肺科医院|therapy

分享至

前言

2024年IASLC世界肺癌大会（WCLC）将于当地时间9月7-10日在美国圣迭戈举行。WCLC是致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤学会议，每届都有来自全球100多个国家的7000多名专业人士参会，共同探讨肺癌和其他胸部恶性肿瘤的前沿诊疗进展。

目前，官网披露了入选本次大会的摘要标题（LBA除外），医脉通整理了IASLC-CSCO-CAALC联席会议部分、口头报告（Oral）部分和简短口头报告（Mini Oral）部分的中国研究成果，让我们先睹为快！

Workshop

IASLC-CSCO-CAALC联席会议-预防和循证医学：全球肺癌的过去和未来

摘要号：WS02.05

标题：Lung Cancer Prevention and Biomarker- Guided Treatment in China During the Last Half Century

讲者：白春学（复旦大学附属中山医院）

摘要号：WS02.07

标题：Immunotherapy for Lung Cancer: What Is on the Horizon?

讲者：刘思阳（暨南大学附属第一医院）

摘要号：WS02.10

标题：Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC)

讲者：吴楠（北京大学肿瘤医院）

摘要号：WC02.11

标题：Dynamic ctDNA-MRD Indicates Pathological Benefits of Additional Neoadjuvant Chemoimmunotherapy Courses for Locally Advanced NSCLC

讲者：D. Lin（上海市第一人民医院）

摘要号：WC02.12

标题：Interim Analysis of A Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)

讲者：钟文昭（广东省人民医院）

摘要号：WS02.14

标题：Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Multicenter Study

讲者：Z. Ma（中国医学科学院肿瘤医院）

摘要号：WS02.15

标题：A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC

讲者：王永生（四川大学华西医院）

摘要号：WS02.16

标题：Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation

讲者：黄婕（广东省人民医院）

摘要号：WS02.17

标题：Updated Event-FreeSurvival of Tislelizumab Plus Chemotherapy Asneoadjuvant/Adjuvant Therapyfor Stage IIB-IIIC NSCLC (LungMark Study)

讲者：林耀彬（中山大学肿瘤防治中心）

摘要号：WS02.18

标题：Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer

讲者：L. Chen（广东省人民医院）

摘要号：WS02.20

标题：Overcoming Immunotherapy Resistance in Non-Small Cell Lung Cancer with a Triple Combination Therapy: Efficacy and Mechanisms

讲者：Y. Xu（上海市肺科医院）

摘要号：WS02.21

标题：Targeted Therapy or Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFRm Lung Adenocarcinoma: A Study Between Four Cohorts

讲者：F-L. Lu（北京大学肿瘤医院）

摘要号：WS02.22

标题：MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)

讲者：刘思阳（暨南大学附属第一医院）

摘要号：WS02.23

标题：EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

讲者：L. Wang（南京鼓楼医院）

Oral

摘要号：OA01.04

标题：A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer

讲者：X. Zhao（天津医科大学肿瘤医院）

摘要号：OA02.03

标题：A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

讲者：熊安稳（上海市肺科医院）

摘要号：OA03.04

标题：Deep Muitiple Instance Learning-Enabled Gene Mutation Prediction of Lung Cancer from Histopathology Images

讲者：S. Xiong（广州医科大学第一附属医院）

摘要号：OA04.05

标题：SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), In Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC)

讲者：王洁（中国医学科学院肿瘤医院）

摘要号：OA05.03

标题：Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial

讲者：S. Yang（上海肺科医院）

摘要号：OA05.05

标题：Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer

讲者：傅睿（广东省人民医院）

摘要号：OA05.06

标题：Radiotherapy Combined with Enhanced Immunotherapy for NSCLC

讲者：C. Miao（山东第一医科大学附属肿瘤医院）

摘要号：OA06.03

标题：SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1

讲者：吴一龙（广东省人民医院）

摘要号：OA07.03

标题：The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients

讲者：Y. Yuan（中山大学肿瘤防治中心）

摘要号：OA07.05

标题：Phase 3 Study of HR20013 For Prevention of Cisplatin-based Chemotherapy-induced Nausea and Vomiting (PROFIT Study)

讲者：张力（中山大学肿瘤防治中心）

摘要号：OA14.03

标题：KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study

讲者：周清（广东省人民医院肿瘤医院）

摘要号：OA15.05

标题：Single-Cell Spatial Architectures of Paratumor Zone Determines the Prognosis of Multiple Lung Cancers

讲者：X. Yuan（北京大学人民医院）

摘要号：OA15.06

标题：Spatiotemporal Genomic and Transcriptomic Analysis Reveal Molecular Landscape and Intratumoral Heterogeneity in Non-Smoking Lung Cancer

讲者：W. Wang（北京大学人民医院）

摘要号：OA16.04

标题：Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-Averexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1

讲者：James CH Yang（台湾大学肿瘤中心）

摘要号：OA16.05

标题：Preliminary Results from a FIH Study of GQ1005, A Novel HER2-ADC, in Patients with Advanced HER2-Expressing Solid Tumors and HER2-Mutated NSCLC

讲者：W. Li（上海市肺科医院）

摘要号：OA18.05

标题：Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial

讲者：Y. Zhu（上海市肺科医院）

Mini Oral

摘要号：MA01.05

标题：Efficacy and Safety of Neoadjuvant Camrelizumab and Apatinib Combined with Chemotherapy in Stage IIIA (N2) NSCLC: A Single Arm, Phase II Trial

讲者：L. Zhao（福建省立医院）

摘要号：MA01.11

标题：Unveiling Gene Expression and Immune Contexture in Stage II/III NSCLC Patients Receiving Neoadjuvant Pembrolizumab and Chemotherapy

讲者：Y. Chen（天津医科大学肿瘤医院）

摘要号：MA02.09

标题：An Effective Multimodel Based on Cell-Free DNA Methylation for Risk Stratification of Pulmonary Nodules

讲者：J-B. Fan（南方医科大学）

摘要号：MA02.13

标题：Deep Learning-Based Multiomic Model for Lung Cancer Diagnosis

讲者：M. Zhao（上海市肺科医院）

摘要号：MA03.03

标题：The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study

讲者：X. Chen（北京大学人民医院）

摘要号：MA03.04

标题：A Deep Learning Model to Predict Occult Lymphatic Metastasis in Clinical Stage I Non-Small Cell Lung Cancer Based on Chest CT

讲者：Y. Fu（上海交通大学医学院附属胸科医院）

摘要号：MA03.05

标题：Intraoperative Visualization of Pulmonary Nodules with Indocyanine Green Inhalation Under Near-Infrared Window I and II

讲者：H. Xu（北京大学人民医院）

摘要号：MA05.03

标题：A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma

讲者：邬麟（湖南省肿瘤医院）

摘要号：MA06.04

标题：Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial

讲者：Z. Li（上海交通大学医学院附属胸科医院）

摘要号：MA06.05

标题：A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy

讲者：吴一龙（广东省人民医院）

摘要号：MA06.07

标题：Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC

讲者：莫树锦（香港中文大学医学院）

摘要号：MA06.11

标题：Phase II Trial of Ensartinib for Advanced or Metastatic Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

讲者：Y. Xia（浙江大学医学院附属第二医院）

摘要号：MA07.04

标题：Targeting CD24 Enhances the Response to Third-Generation Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer

讲者：J. Liang（复旦大学附属中山医院）

摘要号：MA07.08

标题：Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC

讲者：M-M. Zheng（广东省人民医院）

摘要号：MA07.09

标题：Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy

讲者：Z. Yanpei（南方医科大学南方医院）

摘要号：MA07.11

标题：AGRN-Positive Tumor Cells Promoting Immunotherapy Resistance in Lung Adenocarcinoma by Reshaping the Immune Microenvironment

讲者：H. Zhang（电子科技大学附属肿瘤医院）

摘要号：MA07.12

标题：Unleashing the Potential of the Probiotic F.prausnitzii to Optimize PD-1 Inhibitor Efficacy in NSCLC Treatment

讲者：L. Jiang（上海交通大学医学院附属胸科医院）

摘要号：MA07.13

标题：Neoadjuvant Chemotherapy Is Associated with Optimized Spatial Landscape of Tissue-Resident Memory T Cells in Non-Small Cell Lung Cancer

讲者：L. Xing（山东第一医科大学附属肿瘤医院）

摘要号：MA08.03

标题：Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

讲者：F. Fu（复旦大学附属肿瘤医院）

摘要号：MA08.04

标题：Exploration on the Prognostic Heterogenicity in Stage IIB (the 9th Edition of TNM Classification) NSCLC Patients with Different Nodal Statuses

讲者：J-S. Cai（北京大学人民医院）

摘要号：MA09.08

标题：The Mechanical Change and Metastasis Promoting in Lung Adenocarcinoma Progression: From AIS, MIA to IAC

讲者：M. Li（复旦大学附属中山医院）

摘要号：MA09.09

标题：Genomic Mapping of Evolutionary from Pre-Invasive to Advanced Stage in Lung Adenocarcinoma

讲者：Y-D. Lin（广东省人民医院）

摘要号：MA09.10

标题：Spatial Transcriptomics and Next-Generation Sequencing Reveals the Gene Expression Andmolecular Immune Characteristics in LUAD

讲者：Y. Liu（南通大学附属医院）

摘要号：MA09.12

标题：The Role of Different Lepidic Patterns for Determining Whether it is a Multiple Primary Pulmonary Adenocarcinoma

讲者：J. Guo（上海市肺科医院）

摘要号：MA11.03

标题：First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study

讲者：J. Zhou（浙江大学医学院附属第一医院）

摘要号：MA11.04

标题：Nivolumab + Ipilimumab vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS

讲者：吴一龙（广东省人民医院）

摘要号：MA11.07

标题：Preliminary Efficacy and Safety of SHR-1701 Plus Fluzoparib as Maintenance Therapy for Patients with Advanced Lung Squamous Cell Carcinoma

讲者：张永昌（湖南省肿瘤医院）

摘要号：MA11.10

标题：Benmelstobart, a PD-L1 Mab, Plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies:Phase II Results Update

讲者：史美祺（江苏省肿瘤医院）

摘要号：MA11.11

标题：A Phase Ib Study of TQB2618 (Anti-TIM-3) in Combination with Penpulimab and Chemotherapy in Patients with Non-Small Cell Lung Cancer

讲者：邬麟（湖南省肿瘤医院）

摘要号：MA11.12

标题：Peripheral T-Cell Receptor Repertoire Differentiates a Typical Progression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

讲者：J. Han（北京天坛医院）

摘要号：MA12.03

标题：Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI

讲者：W. Li（上海市肺科医院）

摘要号：MA14.04

标题：Global Burden and Trends of Asbestos-Related Thoracic Cancers & Their Associations with National Asbestos Ban Status: A Cross-Sectional Study

讲者：W-Z. Li（广州医科大学附属第一医院）

摘要号：MA14.06

标题：Cost-effectiveness Analysis of Entrectinib in the First-Line Treatment of ROS1+ Locally Advanced or Metastatic NSCLC in China

讲者：Y. Xia（上海罗氏制药有限公司）

摘要号：MA15.04

标题：MRD Predicts Clinical Outcomes of Patients with Early-Stage EGFR-Mutant NSCLC: A Post-Hoc Biomarker Analyses of EVIDENCEMRD

讲者：周斐（上海市东方医院）

摘要号：MA15.05

标题：Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer

讲者：张嘉涛（广东省人民医院）

摘要号：MA15.08

标题：Ultrasensitive Blood Test for Early Lung Cancer: Integrating Fragmentomics and Mutational

讲者：何建行（广州医科大学附属第一医院）

摘要号：MA15.11

标题：Aumolertinib as Adjuvant Therapy in Resectable I-III EGFR-Mutant NSCLC : Also Effective in Patients with High-Risk Relapse Factors

讲者：J. Yao（吉林省人民医院）

摘要号：MA15.12

标题：Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations

讲者：R. Geng（北京协和医院）

摘要号：MA16.10

标题：PIEZO1+ Cancer-associated Fibroblasts Shape an Inert Microenvironment to Suppress Anticancer Immunity in Non-Small Cell Lung Cancer

讲者：M. Zhou（南方医科大学）

摘要号：MA17.04

标题：Longitudinal MRD Monitoring Enhances Prognosis Prediction in 105 Patients with Limited-Stage SCLC Receiving Concurrent Chemoradiotherapy

讲者：y. Yang（中国医学科学院肿瘤医院）

摘要号：MA17.06

标题：Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial

讲者：韩宝惠（上海交通大学附属胸科医院）

摘要号：MA17.07

标题：Safety and Efficacy of Tifcemalimab Combined with Toripalimab in Refractory Extensive Stage Small Cell Lung Cancer

讲者：张立新（吉林省肿瘤医院）

摘要号：MA17.08

标题：Efficacy and Safety of Tislelizumab Plus Anlotinib and 2-Cycle Irinotecan as Second-Line Treatment for ES-Small Cell Lung Cancer(ESTAIL)

讲者：x. Chen（广东省中医院）

摘要号：MA17.12

标题：DLL3-targeted CAR-T Therapy of Small Cell Lung Cancer Utilizing Circular RNA

讲者：邱满堂（北京大学人民医院）

摘要号：MA19.05

标题：Dynamic Immune Profile of Peripheral Blood Predicts Immunotherapy Efficacy and Prognosis in Small Cell Lung Cancer

讲者：邬麟（湖南省肿瘤医院）

摘要号：MA19.08

标题：Transcriptomic Features of Circulating CX3CR1+CD8+ Temra Cells as a Predictor of Chemo-Immunotherapy Response in NSCLC Patients

讲者：Y. Dong（上海市肺科医院）

摘要号：MA19.11

标题：In Vivo CRISPR/Cas9 Library Screening for Target Genes of SCLC Brain Metastasis

讲者：Y. Wang（四川大学）

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

来源：WCLC官网

排版：Squid

执行：Squid

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。

Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.